Implant Sciences deploys systems across 11 European nations over the last six months and continues to see follow-on demand
WILMINGTON, Mass., October 20, 2015, OTCQB, IMSC, /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has completed shipment over 750 QS-B220 Desktop Explosives Trace Detectors across eleven European countries. These systems were sold between April and September, 2015, as EU airports sought to comply with new enhanced explosives screening requirements. Airport authorities that have selected Implant Sciences’ trace detection systems include those located in France, the Netherlands, Norway, Finland, Germany, Belgium, Austria, Poland, the Czech Republic, Cyprus, and Romania.
“Although the majority of these units were shipped and installed for the September 1 EU regulatory deadline for international airports, some orders, such as the 304 unit order to France, required an immediate shipment to the larger airports, with additional units to be shipped in 2016-2017,” stated Dr. Darryl Jones, Implant Sciences’ Executive Vice President, Global Sales and Marketing. “We are also continuing to receive and ship follow-on orders to our customers as these EU airports expand the implementation of ETD screening.”
“Over the past year, in anticipation of increased demand, we took significant steps to augment our production capacity. As a result, even with our unprecedented success in the European market over the last six months, our production team was able to systematically and effectively increase output to fulfill the orders,” stated Dr. Bill McGann, Implant Sciences’ CEO. “With quality at the forefront, we have built a sustainable and scalable production capacity to meet our expected demand for fiscal 2016 and for the years to come.”
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for “Best Security Checkpoint”. All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the “Company”) related thereto contain or may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. Such statements are based on management’s current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company’s control) that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that we may not be able to meet demand for our products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Implant Sciences Corporation
978-752-1700 x 116